No doubt there will be news about progression along the way....

No doubt there will be news about progression along the way. It's like investing in a mining stock that won' be in production until 2024. Each step along the path de-risks the project. So, hopefully the share price rises as the risk decreases.

The antimicrobial safety and effectiveness of BTX 1801 was confirmed in the conference call as being a significant result compared to Bactroban. When the phase 2a results were released, there were a few negative or confused posts on Hot Copper about whether 72.6 % was truly a great result. So, despite the headline "Phase 2a Study Shows BTX 1801 Eradicates S. Aureus", there was some head scratching.

However, as mentioned in the conference call, the new PCR testing, used to determine decolonisation in the BTX 1801 2a study, is more sensitive than the methods used to analyse the 30-year-old Bactroban studies. PCR testing is a genetic test and extremely sensitive and accurate. Whereas the older microscopy and culture testing is a blunt-axe approach – less sensitive at detecting Staph, so results of clearance are falsely higher.

I'm now feeling more confident that the 72.6% clearance rate (i.e. 72.6% of people cleared of Staph) after 5 days of treatment, was indeed a great result, comparable, if not better than Bactroban, but without the risk of antibiotic resistance. Also, the purpose of phase 2b studies is to refine the protocols to improve the results from 2a. So, hopefully, we'll see even better outcomes in the 2b study, which will blow Bactroban out of the water (crossing fingers on that).

There are many cannabinoid companies. But not all are research focused like Botanix, which also has some IP protections. Certainly the Permatrex is IP protected. I'm not 100% sure what other IP protections they have. Does anyone know? It was mentioned a few times in the conference call.

Anyway, one company called Greenwich, which has the only cannaboid product that has passed through all of the clinical trials to be FDA and TGA approved, has a market cap of 6.9 billion. Most of their income comes from Epidolex, which is a cannabinoid product approved to treat epilepsy (see link below). This provides insights into the benefits of clinical trials. It is also important to note that cannabinoids have been under significant pressure from medical authorities for not being evidence-based. The research-based companies are de-risking being tarnished with the old 'Disallowed' criticism that is often used to discredit natural medicines.

https://www.epidiolex.com/